Cost-effectiveness analysis of current treatment of individuals with acute exacerbation of schizophrenia in Bulgaria

References

• Levin C, Chisholm D. Cost-effectiveness and affordability of interventions, policies, and platforms for the prevention and treatment of mental, neurological, and substance use disorders [Internet]. Mental, Neurological, and Substance Use Disorders: Disease Control Priorities, Third Edition (Volume 4). The International Bank for Reconstruction and Development/The World Bank; 2016 [cited 2017 Oct 24]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27227237
   Google Scholar
• Emsley R, Chiliza B, Asmal L, et al. The nature of relapse in schizophrenia. BMC Psychiatr. 2013;13(1):50.
   PubMed Web of Science ®Google Scholar
• Lader M. What is relapse in schizophrenia? Int Clin Psychopharmacol. 1995;9(Suppl 5):5–9.
   PubMed Web of Science ®Google Scholar
• McGrath J, Saha S, Chant D, et al. Schizophrenia: A concise overview of incidence, prevalence, and mortality. Epidemiol Rev. 2008;30(1):67–76.
   PubMed Web of Science ®Google Scholar
• Jablensky A. Worldwide burden of schizophrenia. In: Sadock BJ, Sadock VA, Ruiz P, editors. Kaplan and Sadock’s Comprehensive textbook of psychiatry. 9th ed. Philadelphia (PA): Lippincott Williams & Wilkins; 2009. p. 1451–1462.
   Google Scholar
• Gustavsson A, Svensson M, Jacobi F, et al. Cost of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011;21(10):718–779.
   PubMed Web of Science ®Google Scholar
• Pennington M, McCrone P. The cost of relapse in schizophrenia. Pharmacoeconomics. 2017;35(9):921–936.
   PubMed Web of Science ®Google Scholar
• Trautmann S, Rehm J, Wittchen H-U. The economic costs of mental disorders: Do our societies react appropriately to the burden of mental disorders? EMBO Rep. 2016;17(9):1245–1249.
   PubMed Web of Science ®Google Scholar
• Andrews G, Sanderson K, Corry J, et al. Cost-effectiveness of current and optimal treatment for schizophrenia. Br J Psychiatry. 2003;183:427–435.
   PubMed Web of Science ®Google Scholar
• Knapp M, Beecham J, Koutsogeorgopoulou V, et al. Service use and costs of home-based versus hospital-based care for people with serious mental illness. Br J Psychiatry. 1994;165(2):195–203.
   PubMed Web of Science ®Google Scholar
• Weisbrod BA, Test MA, Stein LI. Alternative to mental hospital treatment. II. Economic benefit-cost analysis. Arch Gen Psychiatry. 1980;37(4)::400–405.
   PubMed Web of Science ®Google Scholar
• Stant AD, Buskens E, Jenner JA, et al. Cost-effectiveness analysis in severe mental illness: outcome measures selection. J Ment Health Policy Econ. 2007;10(2):101–108.
   PubMed Web of Science ®Google Scholar
• Lehman AF, Dixon L, Hoch JS, et al. Cost-effectiveness of assertive community treatment for homeless persons with severe mental illness. Br J Psychiatry. 1999;174:346–352.
   PubMed Web of Science ®Google Scholar
• McCrone P, Craig TKJ, Power P, et al. Cost-effectiveness of an early intervention service for people with psychosis. Br J Psychiatry. 2010;196(5):377–382.
   PubMed Web of Science ®Google Scholar
• Patel A, Mccrone P, Leese M, et al. Cost-effectiveness of adherence therapy versus health education for people with schizophrenia: Randomised controlled trial in four European countries. [cited 2017 Sep 15]; Available from: https://resource-allocation.biomedcentral.com/track/pdf/10.1186/1478-7547-11-12?site=resource-allocation.biomedcentral.com
   Google Scholar
• Slade EP, Gottlieb JD, Lu W, et al. Cost-effectiveness of a ptsd intervention tailored for individuals with severe mental illness. Psychiatr Serv. 2017;68:1225–1231.
   PubMed Web of Science ®Google Scholar
• Lazar SG. The cost-effectiveness of psychotherapy for the major psychiatric diagnoses. Psychodyn Psychiatr. 2014;42(3):423–457.
   PubMedGoogle Scholar
• Kleinman A, Estrin GL, Usmani S, et al. Time for mental health to come out of the shadows. Lancet. 2016;387(10035):2274–2275.
   PubMed Web of Science ®Google Scholar
• Bedrozova A, Gerdjikov I. [Economical aspects of the inpatient psychiatric help in the Republic of Bulgaria.]. Retseptor Bulg Psikhiatr Zhurnal. 2005;2(1):9–21. (in Bulgarian)
   Google Scholar
• Knapp M, Patel A, Curran C, et al. Supported employment: cost-effectiveness across six European sites. World Psychiatry. 2013;12(1):60–68.
   PubMed Web of Science ®Google Scholar
• Alonso J, Petukhova M, Vilagut G, et al. Days out of role due to common physical and mental conditions: results from the WHO World Mental Health surveys. Mol Psychiatry. 2011;16(12):1234–1246.
   PubMed Web of Science ®Google Scholar
• Natsov I. (2012) [Clinical, Epidemiological, Psychometric and Economic Research of Patients with Multiple Somatoform Syndrome in General Medical Practice. [dissertation]. Varna, Bulgaria: Medical University of Varna (in Bulgarian).
   Google Scholar
• Dlouhy M. Mental health policy in Eastern Europe: a comparative analysis of seven mental health systems. BMC Health Serv Res. 2014;14:42.
   Google Scholar
• Raboch J, Kališová L, Nawka A, et al. Use of coercive measures during involuntary hospitalization: findings from ten european countries. Psychiatr Serv. 2010;61(10):1012–1017.
   PubMed Web of Science ®Google Scholar
• Ganev K, Onchev G, Ivanov P, A 16-year follow-up study of schizophrenia and related disorders in Sofia, Bulgaria. Acta Psychiatr Scand. 1998;98(3):200–207.
   PubMed Web of Science ®Google Scholar
• Sartorius N. Stigma and mental health. Lancet (London, England). 2007;370(9590):810.
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO). The ICD-10 classification of mental and behavioural disorders: Clinical descriptions and diagnostic guidelines. Geneva: World Health Organization; 1992. Available from: http://www.who.int/classifications/icd/en/bluebook.pdf.
   Google Scholar
• Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):26261–26276.
   Web of Science ®Google Scholar
• Morosini PL, Magliano L, Brambilla L, et al. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand. 2000;101(4):323–329.
   PubMed Web of Science ®Google Scholar
• Priebe S, Huxley P, Knight S, et al. Application and results of the Manchester short assessment of quality of life (Mansa). Int J Soc Psychiatry. 1999;45(1):7–12.
   PubMed Web of Science ®Google Scholar
• Reinhard SC, Gubman GD, Horwitz AV, et al. Burden assessment scale for families of the seriously mentally ill. Eval Program Plann. 1994;17(3):261–269.
   Web of Science ®Google Scholar
• Chisholm D, Knapp MRJ, Knudsen HC, et al. Client socio-demographic and Service Receipt Inventory – European version : development of an instrument for international research. Br J Psychiatry. 2000;177(39):s39–s33.
   Google Scholar
• National Health Insurance Fund. National Framework for accepting volumes and prices of medical aid for 2015. http://dv.parliament.bg/DVWeb/showMaterialDV.jsp;jsessionid=30845D08DF149A4C7AF78325A5ECD7F8?idMat=91297.
   Google Scholar
• National Center of Public Health and Analyses (NCPHA). Bulletin “Economic analysis of the activities of the medical institutions for hospital care in the public health system in the Republic of Bulgaria for the period 2010–2016”. National Center of Public.
   Google Scholar
• National Center of Public Health and Analyses (NCPHA). Bulletin “Economic analysis of wards in multi-profile hospitals for active treatment for the period 2005-2016. National Center of Public Health and Analyses (NCPHA). 2017; http://ncphp.government.bg.
   Google Scholar
• Ministry of Health, Bulgaria. Methodology for financing of medical establishments in 2016. Ministry of Health, Bulgaria. https://www.mh.government.bg/media/filer_public/2016/04/01/metodika_2016.pdf.
   Google Scholar
• National Council on Prices and Reimburcement of Medical Products. Positive Drug List. Bulgaria. 2017. http://portal.ncpr.bg/registers/pages/register/list-medicament.xhtml.
   Google Scholar
• Ministry Council, Bulgaria. Standards for financing of activities delegated by the state. 2016. http://www.minfin.bg/upload/17188/RMS+276.pdf.
   Google Scholar
• European Central Bank, Eurosystem. Change from 11 April 2017 to 12 April 2018. https://www.ecb.europa.eu/stats/policy_and_exchange_rates/euro_reference_exchange_rates/html/eurofxref-graph-bgn.en.html.
   Google Scholar
• Eurostat: http://appsso.eurostat.ec.europa.eu/nui/submitViewTableAction.do.
   Google Scholar
• Husereau D, Drummond M, Petrou S, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement. 2013 [cited 2017 Oct 24]; Available from: https://www.ispor.org/TaskForces/documents/CHEERS-Statement.pdf
   Google Scholar
• Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ. 2004;13(5):437–452.
   PubMed Web of Science ®Google Scholar
• Ganev K, Onchev G, Ivanov P. RAPyD: Sofia, Bulgaria. In: Hopper K, Harrison G, Janca A, et al., editors. Recovery from schizophrenia: An international perspective. Oxford: Oxford University Press; 2007. p. 227–239.
   Google Scholar
• Zentner N, Baumgartner I, Becker T, et al. Course of health care costs before and after psychiatric inpatient treatment: patient-reported vs. administrative records. Int J Health Policy Manag. 2015;4(3):153–160.
   PubMed Web of Science ®Google Scholar
• Tan-Torres Edejer T, Baltussen R, et al., editors. WHO guide to cost-effectiveness analysis [Internet]. Geneva: WHO; 2003. Available from: http://www.who.int/choice/publications/p_2003_generalised_cea.pdf
   Google Scholar
• Ferrari AJ, Saha S, McGrath JJ, et al. Health states for schizophrenia and bipolar disorder within the Global Burden of Disease 2010 Study. Popul Health Metr. 2012;10(1):16.
   PubMed Web of Science ®Google Scholar